AGREEMENT

TO PURCHASE AND SELL ONE HUNDRED PERCENT (100%)

OF THE ISSUED AND OUTSTANDING SHARES OF

QOLPOM, INC.

AND ITS ASSETS, INTELLECTUAL PROPERTY AND INVENTORY

THIS   AGREEMENT   TO   PURCHASE   AND   SELL   ONE   HUNDRED   PERCENT   (100%)   OF   THE

ISSUED   AND   OUTSTANDING   SHARES   OF   QOLPOM,   INC.   AND   ITS   ASSETS   AND

INVENTORY    ( “ AGREEMENT ” )    IS    MADE    AS    OF    AUGUST    31,    2016    (the    “ EFFECTIVE

DATE ” ) BY AND BETWEEN:

Parallax    Health    Sciences,    Inc.,    a    Nevada    corporation,    with    its    principal

address     at     1327     Ocean     Avenue     Suite     M     Santa     Monica,     CA     90401

( “ PARALLAX ” );

AND

QOLPOM,   Inc.,   an   Arizona   corporation,   with   its   principal   address   at 504   W.

29th St, Tucson, AZ 85713    ( “ QOLPOM ” or “ Selling Entity ” );

AND

David   Bradley ,   Michael   Prudence,   Daniel   J.   Ranieri   and   the   Intellectual

Property    Network,    Inc.    a    Delaware    corporation    represent    one    hundred

(100%)   percent   of   the   shareholders   of   QOLPOM,   with   an   address   at   504   W.

29th St, Tucson, AZ 85713 ( “ Selling Shareholders ” )

WHEREAS ,   Selling   Shareholders   are   the   registered   and   beneficial   owners   of   one   hundred   and

fifty    (150)    shares    of    Common    stock    representing    one    hundred    (100%)    percent    of    the    issued    and

outstanding common shares of the capital stock of QOLPOM (the “ QOLPOM Shares ” ) ; and

WHEREAS ,   PARALLAX   desires   to   buy   and   Selling   Shareholders   desires   to   sell   the   QOLPOM

Shares; and

WHEREAS ,   PARALLAX   desires   to   buy   and   Selling   Shareholders   and   QOLPOM   desire   to   sell

all   of   the   assets   used   in   connection   with   the   business   (the   “ Assets ” )   and   the   inventory   at   the   date   of

Closing ( “ Inventory ” ).

NOW   THEREFORE ,   in   consideration   of   the   premises   and   the   mutual   promises   herein

made, and in consideration of the representations, warranties and covenants herein contained,   and

other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the

Parties agree as follows.

Parllax Health Sciences, Inc QOLPOM, Inc. Purchase and Sale Agreement

Confidential

August 31, 2016

1.

DEFINITIONS

1.1

Definitions.    In  addition  to  definitions  provided  herein,  the  following  terms  have  the

meanings set forth below, unless the context indicates otherwise.

(a)

“ 1933 Act ” means the Securities Act of 1933, as amended.

(b)

“ Agreement ”   means   this   Agreement,   and   all   the   exhibits,   Schedules   and   other

documents    attached    to    or    referred    to    in    this    Agreement,    and    all    amendments    and

supplements, if any, to this Agreement.

(c)

“ Assets ”  means  all  of  the  assets  used  in  connection  with  the  business  of  QOLPOM,

whether   owned   by   Selling   Shareholders   or   QOLPOM.   Specifically   included   in   the   term

Assets   shall   be   each   and   every   license   or   authority   of   any   sort   (a)   used   by   the   Sellers   or

any   employee   or   associate   of   the   Sellers   or   (b)   necessary   for   the   conduct   of   the   business

of the Sellers.

(d)

“ Cash   Earn-out ”   means   the   cash   which   is   to   be   received   based   on   terms   and   conditions

of the Earn-out provision in Section 2.7 paragraph B.

(e)

“ Closing ”   means   the   event   at   which   the   Selling   Shareholders   shall   deliver   to

PARALLAX   the   QOLPOM   Shares   and   QOLPOM   shall   deliver   to   PARALLAX   title   to

the Assets and the Inventory.

(f)

“ Closing  Date ”  means  a  date  mutually  agreed  upon  by  the  Parties  hereto  in  writing

following  the  satisfaction  or  waiver  by  PARALLAX  and  Selling  Shareholders  of  the

conditions precedent specified herein, such date to be no later than September 30, 2016.

(g)

“ Closing  Documents ”  means  the  papers,  instruments  and  documents  required  to  be

executed    and    delivered    on    or    before    the    Closing    Date    pursuant    to    this    Agreement.

Detailed in Section 7 of this Agreement.

(h)

“ Contract ”    means    each    material    contract,    agreement,    license,    permit,    arrangement,

commitment,    instrument    or    contract    to    which    PARALLAX,    QOLPOM    or    Selling

Shareholders is a party.

(i)

“ Copyrights ” means all copyrights in both published works and unpublished works.

(j)

“ COGS ”   Cost   of   Goods   Sold,   are   the   direct   costs   attributable   to   the   production

of   the   products   sold/leased   by   QOLPOM.   This   amount   includes   the   cost   of   the

materials used in creating the products, cost of the lease from the vendor (Phillips)

and  any  direct  labor  costs  used  to  produce  the  products.  It  excludes  indirect

expenses   such   as   distribution   costs   and   sales   force   costs.   COGS   will   be   deducted

from QOLPOM ’ s gross revenue to calculate the “ Adjusted Gross Revenue. ”

(k)

“ Common   Stock   Purchase   Agreement ” ,   means   the   legal   Agreement   issued   by

PARALLAX   to   the   Selling   Shareholders   as   part   of   the   Equity   Consideration   that

memorializes   the   purchase   of   Common   Stock   by   the   Selling   Shareholders   herein

as Schedule “ Q ” .

-2-

Parllax Health Sciences, Inc QOLPOM, Inc. Purchase and Sale Agreement

Confidential

August 31, 2016

(l)

“ Disclose, ”      “ Disclosed ”     and      “ Disclosure ”     means     any     information     and/or

documentation requested by a Party from another Party.

(m)

“ Employment   Agreement ”   means   the   executive   employment   agreement   between

QOLPOM and Nathaniel T.  Bradley.

(n)

“ Employee   Stock   Option   Plan   of   PARALLAX ”   means   the   Parallax   Health   Sciences,

Inc  ( “ PARALLAX ” )  2016  Stock  Option  Plan  is  intended  to  encourage  ownership  of

Shares    of    PARALLAX    by    certain    employees    of    the    Company    or    of    its    Parents    or

Subsidiaries   and   certain   other   Persons,   to   provide   additional   incentive   for them   to   remain

in   the   employ   of   the   Company   or   its   Parents   or   Subsidiaries,   and   to   promote   the   growth

and   success   of   the   Company   and   such   Parents   and   Subsidiaries.   It   is   intended   that   the

Options   issued   pursuant   to   the   Plan   shall   constitute   either   incentive   stock   options   within

the   meaning   of   Section   422   of   the   Code   and   the   regulations   thereunder   or   non-incentive

stock options.

(o)

“ Environmental   Laws ”  means   any   applicable   federal,   state,   municipal   or   local   laws,

regulations,    orders,    governmental    decrees    or    ordinances    concerning    environmental,

health or safety matters.

(p)

“ Evaluation Date ” means the period prior to Aug 31, 2016.

(q)

“ Exchange Act ”   means the United States Securities Exchange Act of 1934, as amended.

(r)

“ Exhibits ” means any supplemental documentation attached hereto and titled “ Exhibit. ”

(s)

“ Equity   Consideration ”   means a   grant from   PARALLAX   to   the   Selling   Shareholders   to

purchase five million (5,000,000) Shares of PARALLAX Common Stock.

(t)

“ Equity   Consideration   Purchase   Price ”   means   the number of   Shares   of Common   stock

that   comprise   the   Equity   Consideration   multiplied   by   the   par   value   of   $.001   per   share   as

well as the Options at the agreed upon strike price below in Section 2.6.

(u)

“ FINRA ” means Financial Industry Regulatory Authority.

(v)

“ GAAP ”  means  generally  accepted  United  States  accounting  principles  applied  in  a

manner consistent with prior periods.

(w)

“ Hazardous   Substance ”   means   any   pollutant,   contaminant,   waste,   special   or   hazardous

waste,   toxic   or   hazardous   substance   which,   when   released   into   the   natural   environment   is

likely   to   cause   harm   or   risk   to   the   natural   environment   or   to   human   or   animal   health,

including   without   limitation,   any   substance   considered   hazardous   under   Environmental

Laws.

(x)

“ Intellectual   Property   Assets ”   means   interest   in   all   intellectual   property   assets

necessary for the operation of PARALLAX or Selling Entity as currently conducted.

(y)

“ Inventory ”   means   all   of   the   medical   and   office   equipment,   durable   medical   equipment,

dispensing   equipment,   and   any   associated   products   used   by   QOLPOM   or   targeted   for

eventual    delivery    by    sale    or    lease    to    customers/patients    or    already    in    a    customer

-3-

Parllax Health Sciences, Inc QOLPOM, Inc. Purchase and Sale Agreement

Confidential

August 31, 2016

environment,   owned   by   and/or in   the   possession   of   QOLPOM, whether   owned   by   Selling

Shareholders or QOLPOM.

(z)

“ IRS ” means Internal Revenue Service.

(aa)

“ Landlords ”   means   Worthe   Real   Estate   Group,   LLC   for   PARALLAX   and   La   Frontera

for QOLPOM.

(bb)

“ La   Frontera   Community   Solutions,   Inc. ”   is   a   non-profit   Arizona   corporation   at   504

W   29 ^th   Street,   Tucson,   AZ   85713   that   provides   outpatient   and   residential   mental   health

and   substance   abuse.   QOLPOM   has   partnered   with   La   Frontera   so   that   QOLPOM   can

utilize    La    Frontera ’ s    unique    call    center    services,    which    use    clinical    professional    to

interact with the clients on the phone.

(cc)

“ Leases ”   means   each   of   the   leases,   subleases,   claims   or   other   real   property   interests   to

which    Selling    Entity    is    a    party    or    is    bound,    and    which    are    legal,    valid,    binding,

enforceable and in full force and effect in all Material respects.

(dd)

“ Liability ”   or    “ Liabilities ”   means    any   direct    or    indirect    indebtedness,    guaranty,

endorsement,   claim,   loss,   damage,   deficiency,   cost,   expense,   obligation   or   responsibility,

fixed    or    unfixed,    known    or    unknown,    asserted    choate    or    inchoate,    liquidated    or

unliquidated, secured or unsecured.

(ee)

“ Loss ”  or   “ Losses ”  mean  any  and  all  demands,  claims,  actions  or  causes  of  action,

assessments,   losses,   damages,   Liabilities,   costs,   and   expenses,   including   without

limitation,    interest,    penalties,    fines    and    reasonable    attorneys,    accountants    and    other

professional  fees  and  expenses,  but  excluding  any  indirect,  consequential  or  punitive

damages,   lost   profits   or   lost   business   opportunities   suffered   by   PARALLAX   or

QOLPOM.

(ff)

“ Marks ”     means     all     functional     business     names,     trading     names,     registered     and

unregistered trademarks, and service marks.

(gg)

“ Material ”  or   “ Materially ”  means  a  matter   that  is  so  substantial  or  important  as  to

reasonably influence the Party to whom   it is made and without which a decision would or

could not be made.

(hh)

“ Material    Adverse    Effect ”    means    any    undisclosed    action,    suit,    judgment,    claim,

demand   or   proceeding   outstanding   or   pending,   or   threatened   against   or   affecting   a   Party

or  which  involves  any  of  the  business,  or  the  properties  or  assets  of  a  Party  that,  if

adversely   resolved   or   determined,   would   have   a   Material   adverse   effect   on   the   business,

operations, assets, properties, prospects, or conditions of a Party taken as a whole.

(ii)

“ OTCQB ”   means   the   quotation   medium   used   for   over-the-counter   equity   securities   that

are not listed on a national stock exchange.

(jj)

PARALLAX ”   means   Parallax   Health   Sciences,   Inc.,   a   corporation   organized   under   the

laws of the State of   Nevada, with its principal address as provided on the first page of this

Agreement, including any subsidiaries.

(kk)

“ PARALLAX Accounting Date ”   means June 30, 2016.

-4-

Parllax Health Sciences, Inc QOLPOM, Inc. Purchase and Sale Agreement

Confidential

August 31, 2016

(ll)

“ PARALLAX   Common   Stock ”   means   as   of   August   30,   2016   the   authorized   capital

stock   and   other   equity   securities   of   PARALLAX   consisting   of   Two   Hundred   and   Fifty

Million  (250,000,000)   shares   of   Common  stock  authorized  and  One   Hundred  Million

Five     Hundred     and     Sixty-Six     Thousand     and     Seven     Hundred     and     Seventy-Four

(100,566,774)    shares  of  Common  stock  issued  and  outstanding  with  a  par  value  of

$0.001.

(mm)      “ PARALLAX  Documents ”  means  all  of   PARALLAX ’ s  documents  contemplated  by

this Agreement.

(nn)

“ PARALLAX   Financial   Statements ”   means   true,   correct,   and   complete   copies   of   the

audited  balance  sheets  of  PARALLAX  and  related  statements  of  operations,  balance

sheet,   cash   flows,   and   changes   in   shareholder ’ s   equity   and   footnotes   for   the   fiscal   years

ended  December  31,   2013  and  December  31,   2014,  and  the  unaudited  balance  sheet,

statement of operations, cash flows and footnotes for the quarter ended March 31, 2016.

(oo)

“ PARALLAX  SEC   Documents ”   means   a   true   and   complete   copy   of   PARALLAX ’ s

Annual   Reports   filed   on   Form   10-K   for   the   year   ending   December   31,   2013,   and   filed   on

Form   10-K   for   the   year   ending   December   31,   2014   and   an   unaudited   draft   10K   for   the

year   ending   December   31,   2015   and   its   Quarterly   Report   filed   on   Form   10-Q   for   the

period   ending   March   31,   2016,   and   Current   Reports,   if   any,   subsequently   filed   with   the

SEC.

(pp)

“ PARALLAX    Stock    Options ” ,    means    the    common    stock    options    that    have    been

authorized   by   the   PARALLAX   Employee   Stock   Option   Plan   that   is   further   defined   in

this Agreement in Definitions (S).

(qq)

“ Party ”  or   “ Parties ”  means  PARALLAX,  QOLPOM  and  the  Selling  Shareholders,

collectively or individually, as the context requires .

(rr)

“ Patents ”   means   all   patents,   patent   applications,   and   inventions,   methods,   processes   and

discoveries that may be patentable.

(ss)

“ Regulatory   Compliance ”   means   all   State   and   Federal   Agencies   that   regulate   In-home

health Monitoring, State and Federal Pharmacy laws and regulations.

(tt)

“ QOLPOM ”   means   QOLPOM,   Inc.,   an   Arizona   Corporation   organized   under   the   laws

of   the   State   of   Arizona,   with   its   principal   address   as   provided   on   the   first   page   of   this

Agreement.

(uu)

“ QOLPOM Interests ” means the QOLPOM Shares, Assets and Inventory.

(vv)

“ QOLPOM Authorized Shares ” means 1,000,000 shares authorized.

(ww)      “ QOLPOM   Shares ”   means   one   hundred   and   fifty   (150)   issued   shares   of   common   stock

that   represent   one   hundred   (100%)   percent   of   the   issued   and   outstanding   common   shares

of QOLPOM, with a par value of $1.00, owned by the Selling Shareholders.

(xx)

“ Sale Shares ” means the five million (5,000,000) shares of PARALLAX Common Stock

that    are    being    sold    to    Selling    Shareholders,    through    a    grant,    as    part    of    the    Equity

Consideration of the Transaction, at par value $0.001.

-5-

Parllax Health Sciences, Inc QOLPOM, Inc. Purchase and Sale Agreement

Confidential

August 31, 2016

(yy)

“ Schedules ”  means  those  schedules  attached  to  this  Agreement  and  as  described  in

Section 1.2.

(zz)

“ SEC ” means the Securities and Exchange Commission.

(aaa)       “ Securities Act ”   means the United States Securities Act of 1933, as amended.

(bbb)      “ Sellers ”    means    the    Selling    Entity    and    the    Selling    Shareholders,    collectively,    or

individually, as the context requires.

(ccc)       “ Sellers ’   Documents ”   means,   all   documents   to   be   provided   by   Sellers   pursuant   to   this

Agreement.

(ddd)      “ Selling Entity ” means QOLPOM, Inc.

(eee)       “ Selling   Entity ’ s   Accounting   Date ”   means,   for   QOLPOM,   the   unaudited   balance   sheet,

statement of operations, cash flows and footnotes from inception to July 31, 2016.

(fff)

“ Selling   Entity ’ s   Documents ”   means   all   of   Selling   Entity ’ s   documents   contemplated   by

this Agreement.

(ggg)      “ Selling Entity ’ s   Financial Statements ” means unaudited financial statements, prepared

under GAAP, which are true, correct, and complete copies of its unaudited balance sheets

for the period since inception.

(hhh)      “ Selling   Shareholders, ”   means   David   Bradley,   Michael   Prudence,   Daniel   J.   Ranieri   and

the   Intellectual   Property   Network,   Inc.   that   collectively   represent   one   hundred   (100%)

percent of the issued and outstanding Shares of the common stock of QOLPOM.

(iii)

“ Stock   Option   Agreement ” ,   means   the   legal   instrument   that   represents   the   number   of

options of common stock in PARALLAX and their strike price.

(jjj)

“ Stock   Option   Consideration ”   means   the   granting   of   Options   to   purchase   the   common

stock   of   PARALLAX   that   PARALLAX   has   provided   as   part   of   its   Consideration   in   the

Sale   and   Purchase   of   one   hundred   (100%)   percent   of   the   issued   and   outstanding   stock   of

QOLPOM and the Assets and Inventory as defined in detail in Section 2

(kkk)      “ Taxes ”   includes   international,   federal,   state,   provincial   and   local   income   taxes,   capital

gains   tax,   value-added   taxes,   franchise,   personal   property   and   real   property   taxes,   levies,

assessments,   tariffs,   duties   (including   any   customs   duty),   business   license   or   other   fees,

sales,   use   and   any   other   taxes   relating   to   the   assets   of   the   designated   party   or   the   business

of   the   designated   party   for   all   periods   up   to   and   including   the   Closing   Date, together   with

any   related   charge   or   amount,   including   interest,   fines,   penalties   and   additions   to   tax,   if

any, arising out of tax assessments.

(lll)

“ Trade Secrets ” means all know-how, confidential information, customer lists, software,

technical   information,   data,   process   technology,   plans,   drawings,   and   blue   prints   owned,

used,   or   licensed   by   a   Party   for   its   business   to   obtain   advantage   over   competitors   who   do

not know or use it, and which are not generally known to the public.

-6-

Parllax Health Sciences, Inc QOLPOM, Inc. Purchase and Sale Agreement

Confidential

August 31, 2016

(mmm)   “ Transaction ”   means   the   purchase   by   PARALLAX   of   the   QOLPOM   Shares,   the   Assets

and the Inventory pursuant to this Agreement.

(nnn)     “ US Certificate ” means the Selling Shareholder ’ s affidavit of non-foreign status.

1.2

Schedules.  The following Schedules are attached to and form part of this Agreement:

Schedule   A

-

Selling Shareholders and Consideration

Schedule   B

-

U.S. Certificate of Selling Shareholders

Schedule   C

-

Directors and Officers of Selling Entity

Schedule   D

-

PARALLAX Board Resolution to Approve Acquisition

Schedule   E

-

PARALLAX Treasury Order

Schedule   F

-

QOLPOM ’ s Corporate Documents

Schedule   G

-

QOLPOM Intellectual Property

Schedule   H

-

QOLPOM Intellectual Property Assignment

Schedule   I

-

QOLPOM Board Resolution to Approve Sale

Schedule   J

-

QOLPOM Shares

Schedule   K

-

QOLPOM Regulatory Licenses

Schedule   L

List of all i(in)ventor-y and assets of QOLPOM

Schedule   M

-

Directors and Officers of PARALLAX

Schedule   N

-

PARALLAX Corporate Documents

Schedule   O

-

QOLPOM Power of Attorney to Transfer Shares

Schedule   P

-

Executive Employment Agreement

Schedule   Q

-

PARALLAX Common Stock Purchase Agreement

Schedule   R

-

PARALLAX Employee Stock Option Plan

Schedule   S

-

PARALLAX Common Stock Options

Schedule   T

-

QOLPOM-Lafrontera Royalty Agreement

Schedule   U

-

QOLPOM Agreements

Schedule   V

-

QOLPOM Officers Certificate

Schedule   W

-

PARALLAX Officers Certificate

1.3

Currency.   All   references   to   currency   referred   to   in   this   Agreement   are   in   United   States

Dollars (US $), unless expressly stated otherwise.

2.

PURCHASE AND SALE OF QOLPOM SHARES; INVENTORY, ASSETS &

INTELLECTUAL PROPERTY

2.1

Purchase   and   Sale   of   QOLPOM   Shares.     At   the   Closing   Selling   Shareholders  hereby

sells,   assigns   and   transfers   to   PARALLAX,   and   PARALLAX   hereby   purchases   from   Selling

Shareholders   the   QOLPOM   Shares,   as   long   as   PARALLAX   has   fully   complied   with   Section   2.5   and   2.6

of the Agreement.

2.2

Inventory   Purchase.      Sellers   at   the   Closing   hereby   sell,   assign   and   transfer   to

PARALLAX, and PARALLAX hereby purchases from Sellers the Inventory of QOLPOM.

2.3

Intellectual   Property.

Sellers   agree   to   sell   and   or   assign   all   Intellectual   Property   as

defined    in    Schedule    “ G ” ,    to    include    but    not    be    limited    to    Patents,    Patent    Pending    Applications,

Trademarks   and   Copyrights   and   or   draft   versions   of   any   of   the   identified   Intellectual   Property   named   in

Section 2.3 and the Assignment of the Intellectual Property defined in Schedule   “ H ” of this Agreement.

-7-

Parllax Health Sciences, Inc QOLPOM, Inc. Purchase and Sale Agreement

Confidential

August 31, 2016

2.4

Asset Purchase.     Sellers   agree   to   sell   and   or   assign   all   assets   of   QOLPOM,   to   include,

but not be limited to physical assets to PARALLAX, as defined in Schedule   “ L ” ,

2.5

Equity    Consideration.     As    consideration    for    the    purchase    of    the    QOLPOM    Shares,

PARALLAX   grants to   Selling   Shareholders the   right to   purchase, at par value   $.001, the   PARALLAX   Sale

Shares, which shall be 5,000,000 (Five Million) shares of PARALLAX common stock, which right shall be

exercised by Selling Shareholders by giving written notice by 5:00 p.m. on August 31, 2016 to PARALLAX

of   the   amount   of   Sale   Shares   that   the   Selling   Shareholders   wishes   to   purchase   as   of   the   Closing   and   by

delivering a check to PARALLAX at the Closing for payment of such amount of Sale Shares.

2.6

Stock   Option   Consideration.

QOLPOM   Shareholders   will   be   granted   two   million

five   hundred   thousand   (2,500,000)   options   that   will   vest   over   three   (3)   years   and   have   multiple   strike

prices set forth as:

A.

500,000 options granted for the first full year from the date of the signing of the     Sale

and Purchase Agreement that vest quarterly commencing at the end of the first       quarter

after

the

issuance of the options and the options will have a strike price of ten

($.10)  cents  attached  hereto  in

Schedule “ S ”

B.

1,000,000   options   first   full   year   from   the   date   of   the   signing   of   the   Sale   and

Purchase Agreement that vest quarterly commencing at the end of the first quarter after      the

issuance of the options and the options will have a strike price of fifteen ($.15) cents

attached   hereto

in Schedule “ S ”

C.

1,000,000   options   first   full   year   from   the   date   of   the   signing   of   the   Sale   and

Purchase Agreement that vest quarterly commencing at the end of the first quarter after      the

issuance of the options and the options will have a strike price of twenty-five ($.25)

cents     attached

hereto in Schedule “ S ”

2.7

Cash   Consideration.     As   partial   consideration   for   the   purchase   of   the   QOLPOM   Shares,

Inventory, Assets, Intellectual Property La Frontera Community Solutions, Inc. ( “ La Frontera ” ) will be paid

up to two million ($2,000,000) dollars through an Earn-Out from   the Adjusted Gross Revenue generated by

the QOLPOM business.

A.

Adjusted   Gross   Revenue.   For   the   purposes   of   this   Agreement,   Adjusted   Gross   Revenue

will be will be defined as cash available to be distributed after Cost of Goods Sold (COGS).

B.

Cash Earn-Out Schedule.

i.

La Frontera will be paid ten (10%) percent of the Adjusted Gross

Revenue up to one million ($1,000,000) dollars net monies received from the sale

of QOLPOM Hardware and Monitoring services; and

ii.

La Frontera will be paid seven (7%) percent of the Adjusted Gross

Revenue after it has received one million ($1,000,000) dollars of net monies

received from the sale of QOLPOM Hardware and monitoring services.

2.8

Royalty   Fee.     La   Frontera   will   receive   a   Royalty   Fee   equal   to   three   (3%)   percent   of   the

gross  revenue  generated  from  the  sale  of  QOLPOM  hardware  and  Service  Fees  associated  with  the

monitoring service as defined in Schedule “ T ” .

-8-

Parllax Health Sciences, Inc QOLPOM, Inc. Purchase and Sale Agreement

Confidential

August 31, 2016

2.9

Key    Management.

Nathan    Bradley    will    enter    into    an    Executive    Employment

Agreement   with   QOLPOM   for   a   period   of   not   less   than   four   (4)   years   from   Closing.   The   BRADLEY

employment agreement is further defined and included in the Agreement as Schedule “ P ” ..

2.10

Payment   of   Cash   Consideration.     The   cash   consideration   of   Two   Million   Dollars   paid

through the Cash Earn-Out defined in Section 2.7 of this Agreement.

2.11

Issuance  of  Equity  Consideration.    The  PARALLAX  Sale  Shares  shall  be  issued  to

Selling Shareholders effective on or before September 30, 2016.

2.12

Selling   Shareholders ’   Share   Delivery   Procedure.   The   Selling   Shareholders   shall   deliver

the    certificate    representing    the    QOLPOM    Shares    at    the    Closing    by    delivering    such    certificate    to

PARALLAX  duly  executed  and  endorsed  in  blank  (or  accompanied  by  duly  executed  stock  powers

endorsed in blank), in each case in proper form for transfer, with signatures guaranteed, and, if applicable,

with   all   stock   transfer   and   any   other   required   documentary   stamps   affixed   thereto,   and   with   appropriate

instructions to allow the transfer agent to transfer the QOLPOM Shares to the name of PARALLAX.

2.13

PARALLAX ’ s   Share   Delivery   Procedure.      PARALLAX    shall   deliver   to   Selling

Shareholders  on  or  before  September  30,  2016  and  after  the  Closing  the  certificate  representing  the

PARALLAX   Sale   Shares   by   delivering   such   certificate   to   Selling   Shareholders   or   Selling   Shareholders ’

attorney,   duly   executed   and   endorsed   in   blank   (or   accompanied   by   duly   executed   stock   powers   endorsed

in   blank),   in   each   case   in   proper   form   for   transfer,   with   signatures   guaranteed,   and,   if   applicable,   with   all

stock    transfer    and    any    other    required    documentary    stamps    affixed    thereto,    and    with    appropriate

instructions   to   allow   the   transfer   agent   to   transfer   the   PARALLAX   Sale   Shares   to   the   name   of   Selling

Shareholders.

2.14

Closing   Date.   A   date   mutually   agreed   upon   by   the   Parties   hereto   in   writing   following   the

satisfaction   or   waiver   by   PARALLAX   and   Selling   Shareholders   of   the   conditions   precedent   specified

herein, such date to be in any event no later than September 30, 2016.

2.15

Restricted   Shares.    Selling   Shareholders   acknowledges   that   the   PARALLAX   Sale   Shares

will   have   such   hold   periods   as   are   required   under   applicable   securities   laws   and   as   a   result   may   not   be

sold,   transferred   or   otherwise   disposed   of,   except   pursuant   to   an   effective   registration   statement   under   the

Securities  Act,  or  pursuant  to  an  exemption  from,  or  in  a  transaction  not  subject  to  the  registration

requirements of the Securities Act, and in each case only in accordance with all applicable securities laws.

2.16

Exemptions.   Selling   Shareholders   acknowledges   that   PARALLAX   has   advised   Selling

Shareholders   that   PARALLAX   is   relying   upon   the   representations   and   warranties   of   Selling   Shareholders

set    out    in    the    US    Certificate    to    issue    the    PARALLAX    Sale    Shares    under    an    exemption    from    the

prospectus and registration requirements of the 1933 Act and, as a consequence, certain protections, rights

and   remedies   provided   by   the   1933   Act,   including   statutory   rights   of   rescission   or   damages,   will   not   be

available to Selling Shareholders.

2.17

QOLPOM   Bank   Accounts.    The   parties   agree   that   the   funds   in   any   current   bank   accounts

of   Selling   Entity   will   remain   in   place   as   corporate   bank   accounts   and   acknowledge   that   PARALLAX

Chief Financial Officer, Calli Bucci will become a signatory to the corporate bank accounts of QOLPOM.

2.18

Non-Compete.   As   part   of   the   consideration,   Selling   Shareholders   agrees   that   as   of   the

Closing   Date   and   through   September   30,   2020   Bradley   will   work   exclusively   for   PARALLAX   pursuant

to   that   document   titled   Employment   Agreement   made   between   PARALLAX   and   BRADLEY   effective   as

of   September   30,   2016   and   will   not   provide   services   for   any   other   entity   that   provides   remote   healthcare

-9-

Parllax Health Sciences, Inc QOLPOM, Inc. Purchase and Sale Agreement

Confidential

August 31, 2016

monitoring  or  related  services,  without  written  approval  from  the  President  of  PARALLAX.  Selling

Shareholders   acknowledges that because of Selling Shareholders ’   position, Selling Shareholders   will have

access   to   material   intellectual   property   and   Confidential   Information.   Selling   Shareholders   shall   not,   for

Selling   Shareholders   or   any   third   party,   directly   or   indirectly   through   September   30,   2020   (a)   divert   or

attempt to divert from   PARALLAX any business of any kind, including without limitation the solicitation

of   or   interference   with   any   of   its   customers,   clients,   members,   business   partners   or   suppliers,   or   (b) solicit

or   otherwise   induce   any   person   employed   by   the   PARALLAX   to   terminate   his   or   her   employment   with

PARALLAX.

2.19

Product   Sourcing   Agreements.    The   parties   agree   that   the   acquisition   of   certain   products

on   satisfactory   terms   is   integral   to   the   current   business   of   QOLPOM   and   will   be   integral   to   the   future

development   and   expansion   of   the   business   of   QOLPOM.   The   parties   shall   agree   on   the   identity   of   and

providers of such products and the   Sellers will cause QOLPOM to enter into product sourcing agreements

with  such  providers  on  terms  specified  by  and  satisfactory  to  PARALLAX.  Such  product  sourcing

agreements are Material contracts of QOLPOM

3.

REPRESENTATIONS AND WARRANTIES OF SELLERS

As    of    the    Closing,    Sellers    make    the    following    representations    and    warranties    to

PARALLAX,   and   acknowledge   that   PARALLAX   is   relying   upon   such   representations   and   warranties   in

connection    with    the    execution,    delivery    and    performance    of    this    Agreement,    notwithstanding    any

investigation made by or on behalf of PARALLAX.

3.1

Organization  and  Good  Standing.      Selling    Entity  is  a  corporation  or  company    duly

organized,   validly  existing  and  in  good  standing  under   the   laws   of   the   State   of  Arizona   and  has   the

requisite corporate power and authority to own, lease and to carry on its business as now being conducted.

Complete  and  correct  copies  of  Selling  Entity ’ s  articles  of  incorporation  or  articles  of  organization,

including    amendments,    and    bylaws    or    operating    agreement,    have    been    disclosed    pursuant    to    this

Agreement and are listed on Schedule “ F ” .

3.2

Authority.    Sellers   have   all requisite   corporate   power   and   authority   to   execute   and   deliver

this Agreement and Sellers ’ Documents to be signed by Sellers and to perform their obligations hereunder

and   to   consummate   the   transactions   contemplated   hereby.    Selling   Entity ’ s   respective   board   of   directors

has    duly    authorized    the    execution    and    delivery    of    each    of    Sellers ’    Documents    by    Sellers    and    the

consummation   of   the   transactions   contemplated   hereby.   No   other   corporate   or   shareholder   proceedings

on  the  part  of  Sellers  are  necessary  to  authorize  such  documents  or  to  consummate  the  transactions

contemplated   hereby.   This   Agreement   has   been,   and   the   other   Sellers ’   Documents   when   executed   and

delivered   by   Sellers   as   contemplated   by   this   Agreement   will   be,   duly   executed   and   delivered   by   Sellers.

This    Agreement    is,    and    the    other    Sellers ’    Documents    when    executed    and    delivered    by    Sellers    as

contemplated hereby will be, valid and binding obligations of Sellers enforceable in accordance with their

respective terms except as limited by:

(a)

applicable   bankruptcy,   insolvency,   reorganization,   moratorium,   and   other   laws   of   general

application affecting enforcement of creditors ’ rights generally;

(b)

laws    relating    to    the    availability    of    specific    performance,    injunctive    relief,    or    other

equitable remedies; and

(c)

public policy.

-10-

Parllax Health Sciences, Inc QOLPOM, Inc. Purchase and Sale Agreement

Confidential

August 31, 2016

3.3

Capitalization.    The   QOLPOM   Shares   are   set   forth   on   Schedule   “ J ”   and   each   have   a   par

value   $1.00   per   share   and   have   been   duly   authorized,   are   validly   issued,   were   not   issued   in   violation   of

any   pre-emptive   rights   and   are   fully   paid   and   non-assessable,   are   not   subject   to   pre-emptive   rights   and

were   issued   in   full   compliance   with   the   laws   of   the   State   of   Arizona   and   each   of   the   Selling   Entity ’ s

articles   of   incorporation, articles   of   organization, bylaws   and/or   operating   agreement   as   applicable.    There

are    no    outstanding    options,    warrants,    subscriptions,    conversion    rights,    or    other    rights,    agreements,    or

commitments   obligating   Selling   Entity   to   issue   any   additional   common   shares   or   units   of   Selling   Entity ’ s

shares or units, or any other securities convertible into, exchangeable for, or evidencing the right to subscribe

for   or   acquire   from   Selling   Entity   any   shares   or   units.   There   are   no   agreements   purporting   to   restrict   the

transfer   of   the   QOLPOM   Shares,   no   voting   agreements,   shareholders ’   agreements,   voting   trusts,   or   other

arrangements restricting or affecting the voting of the QOLPOM Shares.

3.4

Shareholder   of   the   Selling   Entity.    As   of   the   Closing   Date, the   Selling   Shareholders   owns

all QOLPOM Shares.

3.5

Directors   and   Officers   of   Selling   Entity.     The   duly   elected   or   appointed   directors   and

officers of Selling Entity are as set out in Schedule “ C ” .

3.6

Corporate   Records   of   Selling   Entity.    The   corporate   records   of   Selling   Entity,   as   required

to   be   maintained   by   it   pursuant   to   all   applicable   laws,   are   accurate,   complete   and   current   in   all   Material

respects,   and   the   minute   books   of   Selling   Entity   are,   in   all   Material   respects,   correct   and   contain   all

records   required   by   all   applicable   laws,   as   applicable,   in   regards   to   all   proceedings,   consents,   actions   and

meetings of the shareholders, unit holders and board of directors of Selling Entity.

3.7

Non-Contravention.    The   Parties   acknowledge   and   agree   that   Sellers   are   parties to   certain

Disclosed  Contracts  provided  pursuant  to  this  Agreement,  which  may  contain  various  provisions  or

conditions  that   may  affect   the  Transaction  contemplated  hereunder.     The  Parties  agree  that   they  will

discuss   these   issues   and   that   at   or   prior   to   Closing,   these   issues   will   be   addressed   and   resolved   to   the

reasonable   satisfaction   of   the   Parties,   and   any   other   parties   to   the   Contracts,   such   that   the   Transaction   can

be   completed.   Upon   such   satisfaction   by   and   among   the   Parties   and   the   other   parties   to   the   Contracts,

Sellers   represent   that   to   the   best   knowledge   of   Sellers,   neither   the   execution,   delivery   or   performance   of

this Agreement, nor the consummation of the Transaction, will:

(a)

conflict   with,   result   in   a   violation   of,   cause   a   default   under   (with   or   without   notice,   lapse

of  time  or  both)  or  give  rise  to,  a  right  of  termination,  amendment,  cancellation  or

acceleration   of   any   obligation   contained   in   or   the   loss   of   any   Material   benefit   under,   or

result in the creation of any lien, security interest, charge or encumbrance upon any of the

Material   properties   or   assets   of   Selling   Entity   under   any   term,   condition   or   provision   of

any  loan  or  credit  agreement,  note,  Note,  bond,  mortgage,  indenture,  lease  or  other

agreement,   instrument,   permit,   license,   judgment,   order,   decree,   statute,   law,   ordinance,

rule   or   regulation   applicable   to   Selling   Entity,   or   any   of   its   respective   Material   property

or assets;

(b)

violate   any   provision   of   the   articles   of   incorporation,   articles   of   organization,   bylaws,

operating  agreement  or  any  other  organizational  documents  of  Selling  Entity  or  any

applicable laws; or

(c)

violate  any  order,  writ,  injunction,  decree,  statute,  rule,  or  regulation  of  any  court  or

governmental   or   regulatory   authority   applicable   to   Selling   Entity   or   any   of   its   respective

Material property or assets.

-11-

Parllax Health Sciences, Inc QOLPOM, Inc. Purchase and Sale Agreement

Confidential

August 31, 2016

3.8

Actions   and   Proceedings.     To   the   best   knowledge   of   Sellers,   there   is   no   basis   for   and

there   is   no   undisclosed   action,   suit,   judgment,   claim,   demand   or   proceeding   outstanding   or   pending,   or

threatened   against   or   affecting   Selling   Entity   or   which   involves   any   of   the   business,   or   the   properties   or

Assets   of   Selling   Entity   that,   if   adversely   resolved   or   determined,   would   have   a   Material   Adverse   Effect

on the business, operations, Assets, properties, prospects, or conditions of Selling Entity taken as a whole.

There   is   no   reasonable   basis   for   any   claim   or   action   that   based   upon   the   likelihood   of   its   being   asserted

and its success if asserted, would have such a Material Adverse Effect on Sellers.

3.9

Environmental.     To   the   best   knowledge   of   Sellers,   Selling   Entity   has   not   violated   any

Environmental   Laws   and   for   greater   certainty,   without   limitation,   to   the   best   knowledge   of   Sellers,   other

than as contained in Disclosures provided pursuant to this Agreement:

(a)

Selling   Entity   has,   at   all   times   in   relation   to   its   business,   received,   handled,   used,   stored,

treated,    shipped    and    disposed    at    all    times    of    all    Hazardous    Substances    in    strict

compliance with all Environmental Laws;

(b)

There have been   no   spills, releases, deposits or discharges of Hazardous Substances on   or

near the land or premises subject to the Leases;

(c)

Except  as  contained  in  Disclosures  provided  pursuant  to  this  Agreement,  there  are  no

underground storage vessels located on land subject to Selling Entity ’ s Leases;

(d)

No   orders,   directions   or   notices   have   been   issued   under   any   Environmental   Laws   relating

to Selling Entity.

3.10

Compliance.

(a)

To the best knowledge of Sellers, Selling   Entity is in   compliance with, is   not in default or

violation   in   any   Material   respect   under,   and   has   not   been   charged   with   or   received   any

notice   at   any   time   of   any   Material   violation   of   any   statute,   law,   ordinance,   regulation,

rule, decree or other regulation applicable to the business or operations of Selling Entity;

(b)

To   the   best   knowledge   of   Sellers,   Selling   Entity   is   not   subject   to   any   judgment,   order   or

decree   entered   in   any   lawsuit   or   proceeding   applicable   to   its   business   and   operations   that

would constitute a Material Adverse Effect;

(c)

Selling  Entity  has  duly  filed  all  reports  and  returns  required  to  be  filed  by  it    with

governmental     authorities     and     has     obtained     all     governmental     permits     and     other

governmental   consents,   except   as   may   be   required   after   the   execution   of   this   Agreement.

All   of   such   permits   and   consents   are   in   full   force   and   effect,   and   no   proceedings   for   the

suspension   or cancellation   of any   of them, and   no   investigation   relating   to   any   of them, is

pending  or  to  the  best  knowledge  of  Sellers,  threatened,  and  none  of  them  will  be

adversely affected by the consummation of the Transaction; and

(d)

To the best knowledge of Sellers, Selling Entity has operated in Material compliance with

all   laws,   rules,   statutes,   ordinances,   orders   and   regulations   applicable   to   Selling   Entity ’ s

business.   Sellers   have   not   received   any   notice   of   any   violation   thereof,   nor   are   Sellers

aware of any valid basis therefore.

-12-

Parllax Health Sciences, Inc QOLPOM, Inc. Purchase and Sale Agreement

Confidential

August 31, 2016

3.11

Financial    Representations.       Selling    Entity    has    provided    Selling    Entity ’ s    Financial

Statements   which   are   true,   correct,   and   complete   copies   for   the   three   (3)   months   ending   July   31,   2016   for

the Selling Entity ’ s   Accounting Date which are:

(a)

in accordance with the books and records of Selling Entity;

(b)

present   fairly   the   financial   condition   of   Selling   Entity   as   of   the   respective   dates   indicated

and the results of operations for such periods; and

(c)

have been prepared in accordance with GAAP.

Selling   Entity   has   not   received   any   advice   or   notification   from   its   independent   certified   public

accountants   that   Selling   Entity   has   used   any   improper   accounting   practice   that   would   have   the   effect   of

not  reflecting  or  incorrectly  reflecting  in  the  Selling  Entity ’ s  Financial  Statements  or  the  books  and

records   of   Selling   Entity,   any   properties,   assets,   Liabilities,   revenues,   or   expenses.   The   books,   records,

and   accounts   of   Selling   Entity   accurately   and   fairly   reflect,   in   reasonable   detail,   the   assets   and   Liabilities

of   Selling   Entity.     Selling   Entity   has   not   engaged   in   any   transaction,   maintained   any   bank   account,   or

used   any   funds   of   Selling   Entity,   except   for   transactions,   bank   accounts,   and   funds,   which   have   been   and

are reflected in the normally maintained books and records of Selling Entity.

3.12

Absence  of  Undisclosed  Liabilities.     Except   as   contained   in   Selling  Entity ’ s  Financial

Statements,    Schedules    and    Disclosures    provided    pursuant    to    this    Agreement,    Selling    Entity    has    no

Material   Liabilities   or   obligations   either   direct   or   indirect,   matured   or   unmatured,   absolute,   contingent   or

otherwise, which:

(a)

are   not   set   forth   in   Selling   Entity ’ s   Financial   Statements   or   have   not   heretofore   been   paid

or discharged;

(b)

did   not   arise   in   the   regular   and   ordinary   course   of   business   under   any   written   agreement,

contract, commitment, lease or plan; or

(c)

have   not   been   incurred   in   amounts   and   pursuant   to   practices   consistent   with   past   business

practice,   in   or   as   a   result   of   the   regular   and   ordinary   course   of   its   business   since   the   date

of the last Selling Entity ’ s Financial Statements.

3.13

Tax Matters.

(a)

Other  than  as  has  been  Disclosed  pursuant  to  this  Agreement,  Selling  Entity  is  not

presently   under,   and   has   not   received   notice   of,   any   contemplated   investigation   or   audit

by   the   IRS   or   any   foreign   or   state   taxing   authority   concerning   any   fiscal   year   or   period

ended prior to the date hereof;

(b)

All   Taxes   required   to   be   withheld   on   or   prior   to   the   date   hereof   from   employees   for

income   taxes,   social   security   taxes,   unemployment   taxes   and   other   similar   withholding

taxes   have   been   properly   withheld   and,   if   required   on   or   prior   to   the   date   hereof,   have

been deposited with the appropriate governmental agency; and

To  the  best  knowledge  of  Sellers,  other  than  as  has  been  Disclosed  pursuant  to  this

Agreement,   the   Selling   Entity ’ s   Financial   Statements   contain   full   provision   for   all   Taxes

including   any   deferred   taxes   that   may   be   assessed   to   Selling   Entity   for   the   accounting

period ended on the Selling Entity ’ s   Accounting Date or for any prior period in respect of

-13-

Parllax Health Sciences, Inc QOLPOM, Inc. Purchase and Sale Agreement

Confidential

August 31, 2016

any   transaction,   event   or   omission   occurring,   or   any   profit   earned,   on   or   prior   to   the

Selling   Entity ’ s   Accounting   Date   or   for   any   profit   earned   by   Selling   Entity   on   or   prior   to

the   Selling   Entity ’ s   Accounting   Date   or   for   which   Selling   Entity   are   accountable   up   to

such   date,   and   all   contingent   Liabilities   for   Taxes   have   been   provided   for   or   Disclosed

pursuant to this Agreement in the Selling Entity ’ s Financial Statements.

3.14

Filings,   Consents   and   Approvals.     No   filing   or   registration   with,   no   notice   to   and   no

permit,   authorization,   consent,   or   approval   of,   any   public   or   governmental   body   or   authority   or   other

person   or   entity   is   necessary   for   the   consummation   by   Sellers   of   the   Transaction   contemplated   by   this

Agreement   or   to   enable   PARALLAX   to   continue   to   conduct   Selling   Entity ’ s   business   after   the   Closing

Date in a manner which is consistent with that in which the business is presently conducted.

3.15

Personal   Property.     Selling   Entity   possesses,   and   has   good   and   marketable   title   of   all

property   necessary   for   the   continued   operation   of   the   business   of   Selling   Entity   as   presently   conducted

and   as   represented   to   PARALLAX.    All   such   property   is   used   in   the   business   of   Selling   Entity.    All   such

property   is   in   reasonably   good   operating   condition   (normal   wear   and   tear   excepted),   and   is   reasonably   fit

for   the   purposes   for   which   such   property   is   presently   used.   Other   than   as   contained   in   the   Disclosures

provided    pursuant    to    this    Agreement,    all    equipment,    furniture,    fixtures    and    other    tangible    personal

property   and   assets   owned   or   leased   by   Selling   Entity   is   owned   by   Selling   Entity   free   and   clear   of   all

liens, security interests, charges, encumbrances, and other adverse claims.

3.16

Intellectual Property.  To the best of knowledge of Sellers:

(a)

Intellectual   Property   Assets.    As   set   out   in   Schedule   “ G ” ,   Selling   Entity   owns   or   holds   an

interest   in   all   Intellectual   Property   Assets   necessary   for   the   operation   of   the   business   of

Selling   Entity   as   it   is   currently   conducted,   including   all   Marks,   Patents,   Copyrights   and

Trade Secrets.

(b)

Agreements.       Schedule    “ U ”    contains    a    complete    and    accurate    list    and    summary

description,   including   any   royalties   paid   or   received   by   Selling   Entity,   of   all   Contracts

and   agreements   relating   to   the   Intellectual   Property   Assets   to   which   Selling   Entity   is   a

party   or   by   which   Selling   Entity   is   bound,   except   for   any   license   implied   by   the   sale   of   a

product and perpetual, paid-up licenses for commonly available software programs with a

value of less than $500 under which Selling Entity is the licensee.  To the best knowledge

of   Sellers,   there   are   no   outstanding   or   threatened   disputes   or   disagreements   with   respect

to    any    such    license    agreement    other    than    as    contained    in    the    Disclosures    provided

pursuant to this Agreement.

(c)

Intellectual   Property   and   Know-How   Necessary   for   the   Business.    Except   as   set   forth   in

Schedule “ U ” and as Disclosed pursuant to this Agreement, Selling   Entity is the   owner of

all right, title, and interest in and to each of the Intellectual Property Assets, free and clear

of   all   liens,   security   interests,   charges,   encumbrances,   and   other   adverse   claims,   and   has

the   right   to   use,   without   payment   to   a   third   party,   all   of   the   Intellectual   Property   Assets.

Other  than  as  has  been  disclosed  pursuant  to  this  Agreement,  no  employee,  director,

officer   or   shareholder   of   Selling   Entity   owns,   directly   or   indirectly,   in   whole   or   in   part,

any  Intellectual  Property  Asset,  which  Selling  Entity  is  presently  using  or  which  is

necessary   for   the   conduct   of   its   business.    To   the   best   knowledge   of   Sellers,   no   employee

or   contractor   of   Selling   Entity   has   entered   into   any   contract   or   agreement   that   restricts   or

limits   in   any   way   the   scope   or   type   of   work   in   which   the   employee   may   be   engaged   or

requires   the   employee   to   transfer,   assign,   or   disclose   information   concerning   his   work   to

anyone other than Selling Entity.

-14-

Parllax Health Sciences, Inc QOLPOM, Inc. Purchase and Sale Agreement

Confidential

August 31, 2016

(d)

Patents.   Sellers   do   not   hold   any   right,   title   or   interest   in   and   to   any   Patent   not   already

disclosed to PARALLAX, and Sellers have not filed any patent application with any third

party   not   already   disclosed   to   PARALLAX.   To   the   best   knowledge   of   Sellers,   none   of

the   products   manufactured   and   sold,   nor   any   process   or   know-how   used   by   Selling   Entity

infringes   or   is   alleged   to   infringe   any   patent   or   other   patent   proprietary   right   of   any   other

person  or  entity  other  than  as  contained  in  the  Disclosures  provided  pursuant  to  this

Agreement.

(e)

Trademarks.    Selling  Entity  holds  title  and  interest  in  a  Mark  and  Selling  Entity  has

registered   and   filed   an   application   to   register   the   Mark   with   the   United   States   Patent   and

Trademark   Office.    To   the   best   knowledge   of   Sellers,   none   of   the   Marks,   if   any,   used   by

Selling   Entity   infringes   or   is   alleged   to   infringe   any   trade   name,   trademark,   or   service

mark   of   any   third   party   other   than   as   contained   in   the   Disclosures   provided   pursuant   to

this Agreement.

(f)

Copyrights.    Sellers   do   not   hold   any   right,   title   or   interest   in   and   to   any   Copyright,   which

has   been   filed   with   the   United   States   Copyright   Office   that   has   not   been   disclosed   to

PARALLAX, and Sellers have not filed any copyright application with any third party.

(g)

Trade   Secrets.   Each   Seller   has   taken   all   reasonable   precautions   to   protect   the   secrecy,

absolute   right   to   use   the   Trade   Secrets.     The   Trade   Secrets   are   not   part   of   the   public

knowledge  or  literature,  and  to  the  best  knowledge  of  Sellers,  have  not  been  used,

divulged,   or   appropriated   either   for   the   benefit   of   any   person   or   entity   or   to   the   detriment

of Selling   Entity.    No   Trade   Secret is   subject to   any   adverse   claim   or has   been   challenged

or threatened in any way.

(h)

Licensed   Intellectual   Property.   Sellers   are   the   licensees   of   various   patents,   trademarks

and copyrights, all of which are set forth in Schedule “ G ” .

3.17

Employees   and   Consultants.    All   employees   and   consultants   of   Selling   Entity   have   been

paid   all   salaries,   wages,   income   and   any   other   sum   due   and   owing   to   them   by   Selling   Entity   at   the   end   of

the   most   recent   completed   pay   period.   Sellers   are   not   aware   of   any   Labor   conflict   with   any   employees

that   might   reasonably   be   expected   to   have   a   Material   Adverse   Effect   on   Selling   Entity.     To   the   best

knowledge  of   Sellers,   no  employee  of   Selling  Entity   is  in  violation  of  any  term  of  any  employment

contract,    non-disclosure    agreement,    non-competition    agreement    or    any    other    contract    or    agreement

relating   to   the   relationship   of   such   employee   with   Selling  Entity   or   any   other   nature   of   the   business

conducted or to be conducted by Selling Entity.

3.18

Real   Property.    Selling   Entity   does   not   own   any   real   property   of   material   value.    Each   of

the   Leases   to   which   Selling   Entity   is   a   party   or   is   bound,   is   legal,   valid,   binding,   enforceable   and   in   full

force   and   effect   in   all   material   respects.   All   rental   and   other   payments   required   to   be   paid   by   Selling

Entity   pursuant   to   any   such   Leases   have   been   duly   paid   and   no   event   has   occurred   which,   upon   the

passing   of   time,   the   giving   of   notice,   or   both,   would   constitute   a   breach   or   default   by   any   Party   under   any

of   the   Leases.     The   Leases   will   continue   to   be   legal,   valid,   binding,   enforceable   and   in   full   force   and

effect  on  identical  terms  following  the  Closing  Date  unless  otherwise  renegotiated  by  PARALLAX.

Selling   Entity   has   not   assigned,   transferred,   conveyed,   mortgaged,   deeded   in   trust,   or   encumbered   any

interest in the Leases or the leasehold property pursuant thereto.

3.19

Material   Contracts   and   Transactions.   Schedule   “ U ”   attached   hereto   lists   each   Material

Contract   to   which   Selling   Entity   is   a   party.    Each   Contract   is   in   full   force   and   effect,   and   there   exists   no

-15-

Parllax Health Sciences, Inc QOLPOM, Inc. Purchase and Sale Agreement

Confidential

August 31, 2016

Material   breach   or   violation   of   or   default   by   Selling   Entity   under   any   Contract,   or   any   event   that   with

notice   or   the   lapse   of   time,   or   both,   will   create   a   Material   breach   or   violation   thereof   or   default   under   any

Contract  by  Selling  Entity.      Other  than  as  Disclosed  pursuant  to  this  Agreement,  the  continuation,

validity,  and  effectiveness  of  each  Contract  will  in  no  way  be  affected  by  the  consummation  of  the

Transaction   and   there   exists   no   actual   or   threatened   termination,   cancellation,   or   limitation   of,   or   any

amendment, modification, or change to any Contract.

3.20

Certain   Transactions.    Selling   Entity   is   not   a   guarantor   or   indemnitor   of   any   indebtedness

of any third party, including any person, firm or corporation.

3.21

No Brokers.    Selling   Entity has not incurred any independent obligation or liability to any

party for any brokerage fees, agent ’ s commissions, or finder ’ s fees in connection with the Transaction.

3.22

Completeness of Disclosure.    No representation or warranty by Sellers in this Agreement,

nor   any   certificate,   Schedule,   statement,   document   or   instrument   furnished   or   to   be   furnished   to   Sellers

pursuant   hereto,   contains   or   will,   to   the   best   of   Seller ’ s   knowledge,   contain   any   untrue   or   misleading

statement of a Material fact or omit or will omit to state a Material fact required to be stated herein.

3.23

Absence   of   Certain   Changes   or   Events.    Other   than   as   set   forth   in   this   Agreement   or   the

Schedules,   or   as   contained   in   the   Disclosures   provided   pursuant   to   this   Agreement,   since   the   Selling

Entity ’ s   Accounting   Date,   there   has   been   no   Material   change   in   the   business   and   assets   of   Selling   Entity

and   to   the   best   knowledge   of   Selling   Entity ’ s   management,   Selling   Entity   has   not   become   subject   to   any

law  or  regulation  which  Materially  and  adversely  affects,  or  in  the  future  may  adversely  affect  the

business, operations, properties, assets, or condition of Selling Entity.

3.24

PARALLAX     Requests.

Sellers     represent     that     they     have     responded     to     all     of

PARALLAX ’ s  requests  for  information  and  Disclosures  to  the  best  of  their  knowledge  and  agree  to

supplement their responses and Disclosures if additional information is received.

4.

REPRESENTATIONS AND WARRANTIES OF PARALLAX

As   of   the   Closing,   PARALLAX   represents   and   warrants   to   Sellers,   and   acknowledges   that   Sellers   are

relying    upon    such    representations    and    warranties    in    connection    with    the    execution,    delivery    and

performance   of   this   Agreement,   notwithstanding   any   investigation   made   by   or   on   behalf   of   Sellers,   as

follows:

4.1

Organization   and   Good   Standing.    PARALLAX   is   duly   incorporated,   organized,   validly

existing   and   in   good   standing   under   the   laws   of   the   State   of   Nevada   and   has   all   requisite   corporate   power

and  authority  to  own,  lease  and  to  carry  on  its  business  as  now  being  conducted.    PARALLAX  is

qualified   to   do   business   and   is   in   good   standing   as   a   foreign   corporation   in   each   of   the   jurisdictions   in

which it does business, or is otherwise required to do so, where the failure to be so qualified would have a

Material Adverse Effect on the businesses, operations, or financial condition of PARALLAX.

4.2

Authority.   PARALLAX   has   all   requisite   corporate   power   and   authority   to   execute   and

deliver   this   Agreement   and   the   PARALLAX   Documents   to   be   signed   by   PARALLAX   and   to   perform   its

obligations  hereunder  and  to  consummate  the  transactions  contemplated  hereby.    The  execution  and

delivery   of   each   of   the   PARALLAX   Documents   by PARALLAX   and   the   consummation   by   PARALLAX

of   the   transactions   contemplated   hereby   have   been   duly   authorized   by   its   board   of   directors   and   no   other

corporate    or    shareholder    proceedings    on    the    part    of    PARALLAX    is    necessary    to    authorize    such

documents   or   to   consummate   the   transactions   contemplated   hereby.   This   Agreement   has   been,   and   the

other   PARALLAX   Documents   when   executed   and   delivered   by   PARALLAX   as   contemplated   by   this

-16-

Parllax Health Sciences, Inc QOLPOM, Inc. Purchase and Sale Agreement

Confidential

August 31, 2016

Agreement   will   be,   duly   executed   and   delivered   by   PARALLAX   and   this   Agreement   is,   and   the   other

PARALLAX   Documents   when   executed   and   delivered   by   PARALLAX,   as   contemplated   hereby   will   be,

valid  and  binding  obligations  of  PARALLAX  enforceable  in  accordance  with  their  respective  terms,

except as limited by:

(a)

applicable   bankruptcy,   insolvency,   reorganization,   moratorium,   and   other   laws   of   general

application affecting enforcement of creditors ’ rights generally;

(b)

laws    relating    to    the    availability    of    specific    performance,    injunctive    relief,    or    other

equitable remedies; and

(c)

public policy.

4.3

Capitalization   of   PARALLAX.    The   authorized   capital   stock   and   other   equity   securities

were,   One   Hundred   Million   Five   Hundred   and   Sixty-Six   Thousand   and   Seven   Hundred   and   Seventy-Four

(100,566,774)   shares   of   Common   stock   and   outstanding   with   a   par   value   of   $0.001   and   outstanding   with

Eight   Hundred  and  Twenty  Three  Thousand  Six  Hundred  and  Ninety  One  Shares  of  Preferred  stock

issued.

With   the   exception   of   Shares   in   the   amount   of   11,459,279,   which   were   authorized   and   issued

pursuant   to   a   Common   Stock   Purchase   Agreement   entered   into   by   the   Company   on   December   31,   2013,

but   were   never   paid   for   and   are   currently   deemed   by   the   Company   to   be   invalid   and   as   such   are   not

included   on   its   capitalization   table   for   issued   and   outstanding   stock,   all   of   the   issued   and   outstanding

shares   of   PARALLAX   Common   Stock   have   been   duly   authorized,   are   validly   issued,   were   not   issued   in

violation   of   any   pre-emptive   rights   and   are   fully   paid   and   non-assessable,   are   not   subject   to   pre-emptive

rights   and   were   issued   in   full   compliance   with   all   federal,   state,   and   local   laws,   rules   and   regulations.

Except   as   stated   herein,   there   are   no   other   outstanding   options,   warrants,   subscriptions,   phantom   shares,

conversion  rights,  or  other  rights,  agreements,  or  commitments  obligating  PARALLAX  to  issue  any

additional   shares   of   PARALLAX   Common   Stock,   or   any   other   securities   convertible   into,   exchangeable

for,   or   evidencing   the   right   to   subscribe   for   or   acquire   from   PARALLAX   any   shares   of   PARALLAX

Common   Stock   as   of   the   date   of   this   Agreement.     There   are   no   agreements   purporting   to   restrict   the

transfer   of   the   PARALLAX   Common   Stock,   no   voting   agreements,   voting   trusts,   or   other   arrangements

restricting or affecting the voting of the PARALLAX Common Stock.

4.4

Directors  and  Officers  of   PARALLAX.     The  duly  elected  or  appointed  directors  and

officers of PARALLAX are as listed on Schedule “ M ” .

4.5

Corporate   Records   of   PARALLAX.    The   corporate   records   of   PARALLAX,   as   required

to   be   maintained   by   it   pursuant   to   the   laws   of   the   State   of   Nevada,   are   accurate,   complete   and   current   in

all material respects, and   the   minute   book   of   PARALLAX is, in   all material respects, correct and   contains

all   material   records   required   by   the   law   of   the   State   of   Nevada   in   regards   to   all   proceedings,   consents,

actions and meetings of the shareholders and the board of directors of PARALLAX.

4.6

Non-Contravention.   Neither   the   execution,   delivery   or   performance   of   this   Agreement,

nor the consummation of the Transaction, will:

(a)

conflict   with,   result   in   a   violation   of,   cause   a   default   under   (with   or   without   notice,   lapse

of  time  or  both)  or  give  rise  to  a  right  of  termination,  amendment,  cancellation  or

acceleration   of   any   obligation   contained   in   or   the   loss   of   any   Material   benefit   under,   or

-17-

Parllax Health Sciences, Inc QOLPOM, Inc. Purchase and Sale Agreement

Confidential

August 31, 2016

result in the creation of any lien, security interest, charge or encumbrance upon any of the

Material   properties   or   assets   of   PARALLAX   under   any   term,   condition   or   provision   of

any  loan  or  credit  agreement,  note,  Note,  bond,  mortgage,  indenture,  lease  or  other

agreement,   instrument,   permit,   license,   judgment,   order,   decree,   statute,   law,   ordinance,

rule or regulation applicable to PARALLAX or any of its Material property or assets;

(b)

violate     any     provision     of     the     applicable     incorporation     or     charter     documents     of

PARALLAX, or any applicable law; or

(c)

violate  any  order,  writ,  injunction,  decree,  statute,  rule,  or  regulation  of  any  court  or

governmental   or   regulatory   authority   applicable   to   PARALLAX   or   any   of   its   Material

property or assets.

4.7

Validity     of   PARALLAX     Common     Stock     Issuable     upon     the     Transaction.

The

PARALLAX   Sale   Shares   to   be   issued   to   Selling   Shareholders   upon   consummation   of   the   Transaction   in

accordance   with   this   Agreement   will,   upon   issuance,   have   been   duly   and   validly   authorized   and,   when   so

issued   in   accordance   with   the   terms   of   this   Agreement,   will   be   duly   and   validly   issued,   fully   paid   and

non-assessable.

4.8

Actions   and   Proceedings.     To   the   best   knowledge   of   PARALLAX,   there   is   no   claim,

charge,   arbitration,   grievance,   action,   suit,   investigation   or   proceeding   by   or   before   any   federal   or   state

court,    arbiter,    administrative    agency    or    other    governmental    authority    now    pending    or,    to    the    best

knowledge   of   PARALLAX,   threatened   against   PARALLAX   which   involves   any   of   the   stock,   business,

or  the  properties  or  assets  of  PARALLAX  that,  if  adversely  resolved  or  determined,  would  have  a

Material    Adverse    Effect    on    the    business,    operations,    assets,    properties,    prospects    or    conditions    of

PARALLAX   taken   as   a   whole,   other   than   the   lawsuit   disclosed   to   Selling   Shareholders   brought   against

PARALLAX   by   the   former   owner   of   Roxsan   Pharmacy,   Inc.   Shahla   Melamed,   and   the   lawsuit   brought

against   Shahla   Melamed   by   PARALLAX.     Management   believes   that   there   is   no   reasonable   basis   for

Shahla   Melamed ’ s   claim   or   action   that,   based   upon   the   likelihood   of   it   being   asserted   and   its   success   if

asserted, would have such a Material Adverse Effect on PARALLAX.

4.9

Compliance.

(a)

To   the   best   knowledge   of   PARALLAX,   PARALLAX   is   in   compliance   with,   is   not   in

default  or  violation  in  any  Material  respect  under,  and  has  not  been  charged  with  or

received   any   notice   at   any   time   of   any   Material   violation   of   any   statute,   law,   ordinance,

regulation,   rule,   decree   or   other   applicable   regulation   to   the   business   or   operations   of

PARALLAX,  with  the  exception  of  those  violations,  that  include  the  delinquency  in

timely filing of SEC reporting obligations, that has been disclosed to the Seller;

(b)

To   the   best   knowledge   of   PARALLAX,   PARALLAX   is   not   subject   to   any   judgment,

order  or  decree  entered  in  any  lawsuit  or  proceeding  applicable  to  its  business  and

operations that would constitute a Material Adverse Effect;

(c)

PARALLAX    has    duly    filed    all    reports    and    returns    required    to    be    filed    by    it    with

governmental     authorities     and     has     obtained     all     governmental     permits     and     other

governmental   consents,   except   as   may   be   required   after   the   execution   of   this   Agreement.

All   of   such   permits   and   consents   are   in   full   force   and   effect,   and   no   proceedings   for   the

suspension   or cancellation   of any   of them, and   no   investigation   relating   to   any   of them, is

pending   or   to   the   best   knowledge   of   PARALLAX,   threatened,   and   none   of   them   will   be

affected in a Material adverse manner by the consummation of the Transaction; and

-18-

Parllax Health Sciences, Inc QOLPOM, Inc. Purchase and Sale Agreement

Confidential

August 31, 2016

(d)

To   the   best   knowledge   of   PARALLAX,   PARALLAX   has   operated   in   Material

compliance   with   all   laws,   rules,   statutes,   ordinances,   orders   and   regulations   applicable   to

its   business.     PARALLAX   has   not   received   any   notice   of   any   violation   thereof,   nor   is

PARALLAX aware of any valid basis therefore.

4.10

Filings,   Consents   and   Approvals.     No   filing   or   registration   with,   no   notice   to   and   no

permit,   authorization,   consent,   or   approval   of   any  public  or   governmental   body  or   authority  or   other

person   or   entity   is   necessary   for   the   consummation   by   PARALLAX   of   the   Transaction   contemplated   by

this   Agreement   to   continue   to   conduct   its   business   after   the   Closing   Date   in   a   manner   which   is   consistent

with that in which it is presently conducted.

4.11

SEC   Filings.   PARALLAX   has   furnished   or   made   available   to   Sellers   the   PARALLAX

SEC   Documents.   As   of   their   respective   dates,   to   the   best   knowledge   of   PARALLAX,   the   PARALLAX

SEC   Documents   complied   in   all   material   respects   with   the   requirements   of   the   Securities   Act,   or   the

Exchange   Act,   as   the   case   may   be,   and   the   rules   and   regulations   of   the   SEC   thereunder   applicable   to   such

PARALLAX   SEC   Documents,   with   the   exception   of   those   violations,   that   include   the   delinquency   in

timely   filing   of   SEC   reporting   obligations,   that   has   been   disclosed   to   the   Seller.    The   PARALLAX   SEC

Documents   constitute   all   of   the   documents   and   reports   that   PARALLAX   was   required   to   file   with   the

SEC pursuant to the Exchange Act and the rules and regulations promulgated thereunder by the SEC.

4.12

Financial  Representations.     Included  with  the  PARALLAX  SEC  Documents  are  true,

correct,  and  complete  copies  of  audited  and/or  unaudited  Financial  Statements  for  PARALLAX  and

ROXSAN for the interim periods 2013, 2014 and 2015, which are:

(a)

in accordance with the books and records of PARALLAX;

(b)

present   fairly   the   financial   condition   of   PARALLAX   as   of   the   respective   dates   indicated

and the results of operations for such periods; and

(c)

have been prepared in accordance with GAAP.

PARALLAX   has not received any advice or notification from   its independent certified public accountants

that   PARALLAX   has   used   any   improper   accounting   practice   that   would   have   the   effect   of   not   reflecting

or    incorrectly    reflecting    in    the    PARALLAX    Financial    Statements    or    the    books    and    records    of

PARALLAX,   any   properties,   assets,   Liabilities,   revenues,   or   expenses.    The   books,   records,   and   accounts

of    PARALLAX    accurately    and    fairly    reflect,    in    reasonable    detail,    the    assets,    and    Liabilities    of

PARALLAX.   PARALLAX   has   not   engaged   in   any   transaction,   maintained   any   bank   account,   or   used

any   funds   of   PARALLAX,   except   for   transactions,   bank   accounts,   and   funds,   which   have   been   and   are

reflected in the normally maintained books and records of PARALLAX.

4.13

Absence  of  Undisclosed  Liabilities.    Except  as  Disclosed  in  this  Agreement  and  the

PARALLAX   SEC   Documents,   PARALLAX   has   no   Material   Liabilities   or   obligations   either   direct   or

indirect, matured or unmatured, absolute, contingent or otherwise, which:

(a)

are   not   set   forth   in   the   PARALLAX   Financial   Statements   or   have   not   heretofore   been

paid or discharged;

(b)

did    not    arise    in    the    regular    and    ordinary    course    of    business    under    any    agreement,

contract, commitment, lease or plan specifically provided in writing to PARALLAX; or

-19-

Parllax Health Sciences, Inc QOLPOM, Inc. Purchase and Sale Agreement

Confidential

August 31, 2016

(c)

have   not   been   incurred   in   amounts   and   pursuant   to   practices   consistent   with   past   business

practice,   in   or   as   a   result   of   the   regular   and   ordinary   course   of   its   business   since   the   date

of the last PARALLAX Financial Statements.

4.14

Tax Matters.

(a)

PARALLAX   is   not   presently   under   and   has   not   received   notice   of,   any   contemplated

investigation  or  audit  by  the  Internal  Revenue  Service  or  any  foreign  or  state  taxing

authority concerning any fiscal year or period ended prior to the date hereof;

(b)

To   the   best   knowledge   of   PARALLAX,   all   Taxes   required   to   be   withheld   on   or   prior   to

the   date   hereof,   including   but   not   limited   to,   those   pertaining   to   employees   for   income